Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Myung Han | - |
dc.contributor.author | Lee, Eun Seong | - |
dc.contributor.author | Eo, Jae Seon | - |
dc.contributor.author | Kim, Sungeun | - |
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Sung, Jae Sook | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.date.accessioned | 2021-09-01T10:57:47Z | - |
dc.date.available | 2021-09-01T10:57:47Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/63997 | - |
dc.description.abstract | Objectives: This study unravels the significance of cell-free DNA (cfDNA) quantification as a promising measure of the biological behavior/aggressiveness of tumors. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured by positron emission tomography/computed tomography scan enable a precise assessment of metabolic tumor burden. However, their clinical implications in identifying patients who need more aggressive treatment in advanced non-small cell lung cancer (NSCLC) are not fully understood. Materials and methods: In the current prospective trial, we analyzed 101 newly diagnosed advanced NSCLC (stage III-IV) patients with measurable baseline MTV, TLG, and cfDNA quantification. The best cut-offs for cfDNA levels, MTV, and TLG to predict progression-free survival and overall survival were determined using X-tile analysis. Results: There were significant positive correlations between cfDNA and MTV (r = 0.488, p < 0.001) and between cfDNA and TLG (r = 0.554, p < 0.001). High-cfDNA levels and high-MTV/TLG negatively correlated with overall survival (OS) (all p < 0.001). Patients with high-MTV showed similar median OS irrespective of their cfDNA levels (low-cfDNA vs. high-cfDNA = 9.2 vs 6.6 months; p > 0.05). However, patients with low-MTV and low-cfDNA levels showed longer OS than those with low-MTV and high-cfDNA levels (low-cfDNA vs. high-cfDNA = 49.3 vs 11.5 months; p < 0.001). The patient group with low-TLG also showed similar trends. The cfDNA level was an independent prognostic factor for OS by Cox-proportional hazard analysis. Conclusion: Although the patients with high metabolic tumor burden had a poor prognosis, regardless of the biological behavior/aggressiveness of the tumor, patients with low metabolic tumor burden and high cfDNA levels showed a poor prognosis. Taken together, this study indicates a stronger prognostic value of baseline cfDNA levels in identifying patients with advanced NSCLC and personalizing their treatment strategies for better survival. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | TOTAL LESION GLYCOLYSIS | - |
dc.subject | F-18-FDG PET/CT | - |
dc.subject | DEOXYRIBONUCLEIC-ACID | - |
dc.subject | PROGNOSTIC-FACTOR | - |
dc.subject | NUCLEIC-ACIDS | - |
dc.subject | BLOOD-PLASMA | - |
dc.subject | SERUM | - |
dc.subject | SURVIVAL | - |
dc.subject | MARKER | - |
dc.subject | VOLUME | - |
dc.title | Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Eo, Jae Seon | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.contributor.affiliatedAuthor | Sung, Jae Sook | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.contributor.affiliatedAuthor | Park, Kyong Hwa | - |
dc.contributor.affiliatedAuthor | Shin, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1016/j.lungcan.2019.06.014 | - |
dc.identifier.scopusid | 2-s2.0-85067488994 | - |
dc.identifier.wosid | 000478707200023 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, v.134, pp.158 - 166 | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.citation.title | LUNG CANCER | - |
dc.citation.volume | 134 | - |
dc.citation.startPage | 158 | - |
dc.citation.endPage | 166 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | TOTAL LESION GLYCOLYSIS | - |
dc.subject.keywordPlus | F-18-FDG PET/CT | - |
dc.subject.keywordPlus | DEOXYRIBONUCLEIC-ACID | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTOR | - |
dc.subject.keywordPlus | NUCLEIC-ACIDS | - |
dc.subject.keywordPlus | BLOOD-PLASMA | - |
dc.subject.keywordPlus | SERUM | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MARKER | - |
dc.subject.keywordPlus | VOLUME | - |
dc.subject.keywordAuthor | Non-small-cell lung carcinoma | - |
dc.subject.keywordAuthor | Cell-free nucleic acids quantification | - |
dc.subject.keywordAuthor | Metabolic tumor volume | - |
dc.subject.keywordAuthor | Total lesion glycolysis | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.